In vitro activity of ertapenem and other carbapenems against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae clinical isolates in a tertiary care center in Turkey

Bibliography

• Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001;14:933-51
   PubMed Web of Science ®Google Scholar
• Johnson DM, Biedenbach DJ, Jones RN. Potency and antimicrobial spectrum update for piperacillin-tazobactam 2000: emphasis on its activity against resistant organisms populations and generally untested species causing community-acquired respiratory tract infections. Diagn Microbiol Infect Dis 2002;43:49-60
   PubMed Web of Science ®Google Scholar
• Livermore DM, Sefton AM, Scott GM. Properties and potential of ertapenem. J Antimicrob Chemother 2003;52:331-44
   PubMed Web of Science ®Google Scholar
• Wexler HM. In vitro activity of ertapenem: review of recent studies. J Antimicrob Chemother 2004;53(Suppl 2):ii11-21
   PubMed Web of Science ®Google Scholar
• Shah PM, Isaacs RD. Ertapenem, the first of a new group of carbapenems. J Antimicrob Chemother 2003;52:538-42
   PubMed Web of Science ®Google Scholar
• Livermore DM, Oakton KJ, Carter MW, Warner M. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases. Antimicrob Agents Chemother 2001;45(10):2831-7
   PubMed Web of Science ®Google Scholar
• Livermore DM, Carter MW, Bagel S, et al. In vitro activities of ertapenem (MK-0826) against recent clinical bacteria collected in Europe and Australia. Antimicrob Agents Chemother 2001;45:1860-7
   PubMed Web of Science ®Google Scholar
• Fuchs PC, Barry AL, Brown SD. In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers. Antimicrob Agents Chemother 2001;45:1915-8
   PubMed Web of Science ®Google Scholar
• Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk susceptibility tests, 9th edition. Approved standard M2-A9. Clinical and Laboratory Standards Institute, Wayne, PA; 2006
   Google Scholar
• Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 7th edition. Approved standard M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA; 2006
   Google Scholar
• Goossens H, Grabein B. Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC Program in Europe and the United States (1997 – 2004). Diagn Microbiol Infect Dis 2005;53:257-64
   PubMed Web of Science ®Google Scholar
• Leblebicioglu H, Gunaydin M, Esen S, et al. Surveillance of antimicrobial resistance in Gram-negative isolates from intensive care units in Turkey: analysis of data from the last 5 years. J Chemother 2002;14:140-6
   PubMed Web of Science ®Google Scholar
• Ozgunes I, Erben N, Kiremitci A, et al. The prevalence of extended-spectrum beta lactamase-producing Escherichia coli and Klebsiella pneumoniae in clinical isolates and risk factors. Saudi Med J 2006;27:608-12
   PubMed Web of Science ®Google Scholar
• Bradley JS, Garau J, Lode H, et al. Carbapenems in clinical practice: a guide to their use in serious infection. Int J Antimicrob Agents 1999;11: 93-100
   PubMed Web of Science ®Google Scholar
• Kiffer CR, Kuti JL, Eagye KJ, et al. Pharmacodynamic profiling of imipenem, meropenem and ertapenem against clinical isolates of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. from Brazil. Int J Antimicrob Agents 2006;28:340-4
   PubMed Web of Science ®Google Scholar
• Kohler J, Dorso KL, Young K, et al. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum beta-lactamase-and extended-spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob Agents Chemother 1999;43:1170-6
   PubMed Web of Science ®Google Scholar
• Alhambra A, Cuadros JA, Cacho J, et al. In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J Antimicrob Chemother 2004;53:1090-4
   PubMed Web of Science ®Google Scholar
• Sorlózano A, Gutiérrez J, Romero JM, et al. Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli. J Basic Microbiol 2007;47:413-6
   PubMed Web of Science ®Google Scholar
• Hernández JR, Velasco C, Romero L, et al. Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain. Int J Antimicrob Agents 2006;28:457-9
   PubMed Web of Science ®Google Scholar
• Jones RN, Sader HS, Fritsche TR. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn Microbiol Infect Dis 2005;52:71-4
   PubMed Web of Science ®Google Scholar
• Borbone S, Cascone C, Santagati M, et al. Bactericidal activity of ertapenem against major intra-abdominal pathogens. Int J Antimicrob Agents 2006;28:396-401
   PubMed Web of Science ®Google Scholar
• Samaha-Kfoury JN, Kanj SS, Araj GF. In vitro activity of antimicrobial agents against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae at a tertiary care center in Lebanon. Am J Infect Control 2005;33:134-6
   PubMed Web of Science ®Google Scholar
• Colodner R, Samra Z, Keller N, et al. First national surveillance of susceptibility of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. to antimicrobials in Israel. Diagn Microbiol Infect Dis 2007;57:201-5
   PubMed Web of Science ®Google Scholar
• Mody RM, Erwin DP, Summers AM, et al. Ertapenem susceptibility of extended spectrum beta-lactamase-producing organisms. Ann Clin Microbiol Antimicrob 2007;6:6
   PubMedGoogle Scholar
• Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother 2003;47:3442-7
   PubMed Web of Science ®Google Scholar
• Paterson DL, Rossi F, Baquero F, et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005;55:965-73
   PubMed Web of Science ®Google Scholar
• Woodford N, Dallow JW, Hill RL, et al. Ertapenem resistance among Klebsiella and Enterobacter submitted in the UK to a reference laboratory. Int J Antimicrob Agents 2007;29:456-9
   PubMed Web of Science ®Google Scholar
• Elliott E, Brink AJ, van Greune J, et al. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumoniae with an extended-spectrum beta-lactamase. Clin Infect Dis 2006;42:e95-8
   PubMedGoogle Scholar